Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 76515

AbstractMaterial and MethodsResultsDiscussionConclusionAcknowledgementReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"



Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018




Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."



Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018




Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."



Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018




Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."



Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
Lucknow
On Sep 2018




Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."



Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata




Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
Muzaffarnagar.
On Aug 2018




Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".



Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
Bengaluru.
On Aug 2018




Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".



Dr. Mamta Gupta
Consultant
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018




Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.


Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."



Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011




Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."



Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011
Anuradha

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.


Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020

Important Notice

Original article / research
Year : 2022 | Month : April | Volume : 16 | Issue : 4 | Page : EC07 - EC12 Full Version

Expression of Melan-A (MART-1) in Various Pigmented Melanocytic Nevi and Close Mimickers


Published: April 1, 2022 | DOI: https://doi.org/10.7860/JCDR/2022/53438.16154
R Shubha Sangeetha, Prakhar Garg, Nikita Jaju, YA Manjunatha

1. Associate Professor, Department of Pathology, Dr. BR Ambedkar Medical College, Bengaluru, Karnataka, India. 2. Postgraduate, Department of Pathology, Dr. BR Ambedkar Medical College, Bengaluru, Karnataka, India. 3. Postgraduate, Department of Pathology, Dr. BR Ambedkar Medical College, Bengaluru, Karnataka, India. 4. Professor and Head, Department of Pathology, Dr. BR Ambedkar Medical College, Bengaluru, Karnataka, India.

Correspondence Address :
Dr. Prakhar Garg,
Postgraduate, Department of Pathology, Dr. BR Ambedkar Medical College,
Bengaluru, Karnataka, India.
E-mail: prakhargargps@gmail.com

Abstract

Introduction: Melanocytic nevi are neoplasms resulting from the proliferation of melanocytes. Diagnosis of melanocytic tumours can be tricky, considering two factors, diagnosis of origin and determination of its benign or malignant nature. Visualisation of melanin or other pigments are non specific with Hematoxylin and Eosin (H&E) staining and specific with Melan-A Immunohistochemistry (IHC). Intensity and pattern of these reactions shows marked variability in different melanocytic lesions.

Aim: To study the intensity and pattern of Melan-A expression in various pigmented melanocytic nevi and to understand its utility to differentiate close mimickers.

Materials and Methods: A cross-sectional study of 50 lesions (45 cases and 5 controls) was conducted in the Department of Pathology of Dr. B.R. Ambedkar Medical College (tertiary hospital), Bengaluru, Karnataka, India, between September 2020 to October 2021. The skin biopsies received were fixed in formalin and paraffin embedded. Sections were stained with H&E and Melan-A IHC marker, using A103 antibody and a high temperature antigen retrieval was performed. Pattern and intensity of Melan-A expression were studied and its evaluation was done with normal skin (control).

Results: Melan-A showed varied intensity (+ weak; ++ moderate; +++ strong), pattern (patchy, diffuse), distribution and on various pigmented melanocytic lesions and mimickers were analysed. Dermal nevi (18) showed +++ intensity, diffuse pattern in dermis and two cases showed ++ intensity and patchy staining. Five cases of Compound nevi showed ++ intensity, diffuse pattern in Dermoepidermal Junction (DEJ) and dermis, Deep penetrating nevi (in one case) +++ intensity and diffuse pattern in DEJ, dermis. Two cases of pigmented Basal Cell Carcinoma (BCC) showed + intensity and no definitive pattern in dermis. Four cases in fibrohistiocytic lesions and Malignant Peripheral Nerve Sheath Tumour (MPNST) shows negative Melan-A. In control melanocytes show dendritic pattern of staining and melanophages were negative.

Conclusion: Melan-A is specific melanocytic marker as it stains only melanocytic lineage and no other cell types in background thus it is a marker of histogenesis instead of malignancy indicator. It highlights important architectural features and confirms the origin of lesions thus aiding the pathologist towards accurate diagnosis and differentiates from close mimickers.

Keywords

Dermal nevus, Dysplastic nevus, Fibrohistiocytic lesions, Malignant melanoma, Melanoma antigen recognised by T-cells

Melanocytic nevi occur due to proliferation of melanocytes, pigment producing cells in the skin. Nevi results due to clonal proliferation and growth arrest of melanocytes, stimulated by most commonly BRAF oncogenic mutation through Mitogen-Activated Protein Kinase (MAPK) pathway (1). The incidence of Acquired Melanocytic Nevi (AMN) ranges from 15% to 40% (2). The prevalence of nevi is related to the age, race, genetic and environmental factors. Melanocytic nevi usually present in childhood and adolescents with equal sex distribution. It has been estimated that the likelihood of any one nevus evolving into melanoma is roughly 1/1,00,000 and subsequent mortality is of the order of 1/500000 original nevi (3). The size and number of AMN and presence of dysplastic nevi are the leading risk factors that should be recognised in the development of MM (4). Diagnosis of melanocytic tumours poses two big glitches for a histopathologist: 1) To diagnose its origin for accurate diagnosis 2) determination of its benign or malignant nature (5). In some cases, H&E staining cannot prove actual size of melanoma invasion, in these cases immunohistochemical examination with Melan-A can be a complementary method (6).

Many nonmelanocytic skin lesions have pigmented variants such as pigmented Basal Cell Carcinoma (BCC), fibro histiocytic lesions, Malignant Peripheral Nerve Sheath Tumour (MPNST) that can mimic melanocytic lesions. Histopathological examination helps to confirm the clinical diagnosis and helps in treatment of patients with pigmented skin lesions (7). Many lesions create difficulty in histopathological analysis due to overlapping features and dilemma regarding origin of lesions hence, it is of prime importance to develop a diagnostic approach to confirm and differentiate melanocytic lesions and their mimickers by Melan-A IHC marker, this being the prime aim of this study.

Melan-A was cloned by Coulie et al., in 1985 from the human melanoma SK-MEL-29 cell line. Melan-A/MART-1 is an antigen recognised by tumour infiltrating cytotoxic T cells from a melanoma patient. This antigen is a gene product of MART-1 gene. In 1996, Chen YT et al., generated a monoclonal antibody against the recombinant Melan-A protein (8). Immunoblotting and immunoprecipitation analysis exposed a 20-22 kDa doublet in Melan-A positive cell lines and this antibody worked on fixed tissue (9). Two commercially available antibodies are:

1. A103: Mouse monoclonal antibody against Melan-A recombinant protein
2. M2-7C10: Mouse monoclonal antibody clone produced against MART-1 protein

Melan-A is a melanocyte lineage specific marker showing cytoplasmic staining and having no background staining. It is used for differentiating melanocytic nevi from other lesions with resembling H&E aspects, although some authors claim that MART-1 could be used in assessing the prognosis of the patients with melanoma (10).

In this study, the intensity and pattern of Melan-A expression in various pigmented melanocytic nevi were studied in detail to understand its utility to differentiate close mimickers.

Material and Methods

This cross-sectional study was conducted in the Department of Pathology at Dr. BR Ambedkar Medical College (tertiary hospital), Bengaluru, Karnataka, India, from September 2020 to October 2021. A total of 50 lesions (45 cases and 5 controls) were analysed. Ethical Clearance was obtained from Institutional Research Board (reference No. EC-611).

Inclusion and Exclusion criteria: All patients aged between 10-70 years clinically diagnosed as pigmented lesions were included for the study and patient whose biopsy was scant or fragmented tissue bits, who are on steroid and were already on treatment for melanocytic nevi were excluded from the study.

Study Procedure

The following spectrum of clinically diagnosed lesions were included in this study received from Dermatology Department were studied:

Lesions: Dermal nevus, compound nevus, deep penetrating nevus, dysplastic nevus, junctional lentiginous nevus with atypia, spitz nevus, Melanocytic Tumor of Uncertain Malignant Potential (MELTUMP), Malignant Melanoma (MM), Desmoplastic Melanoma (DMM).

Pigmented lesion mimicker: Pigmented BCC, fibro histiocytic lesions, Malignant Peripheral Nerve Sheath Tumour (MPNST).

All relevant clinical details and informed consent has been taken by explaining in his/her own understandable language. Skin biopsies were fixed in 10% formalin, grossed as per prescribed standards, embedded in paraffin, 4 to 5 microns thick sections were processed and stained with haematoxylin and eosin and subjected to histopathological analysis. Lesions were subjected for Melan-A immunohistochemistry, melanin bleaching was performed in selected lesions which showed abundant melanophages on histopathological examination by adding 3% H2O2 on the section for 10 minutes. Using A103 antibody and a high temperature antigen retrieval.

Melan-A expression was interpretated under following headings:

a. Intensity was graded as:
• Negative (-),
• weak (+) when <25% of positively stained cells,
• moderate (++) when 26-50% of positively stained cells,
• Severe (+++) when >50% of positively stained cells (11).
b. Pattern was graded as Patchy (P) and Diffuse (D)
c. In each lesion nevus cells and tumour cells were interpretated in locations such as epidermis, DEJ, dermis, periadnexal and perifollicular region.

Data was tabulated and evaluated with normal skin (control) patterns of melanocytic expression.

Statistical Analysis

The statistical software Statistical Package for the Social Sciences (SPSS) version 22.0 was used for analysis of data in Microsoft excel spreadsheet and word used to generate tables, graphs. Proportions were described as percentages. The data was reported as mean±standard deviation. The lesions were described using numbers and percentage. The basic demographic data was summarised using descriptive statistics.

Results

The expression of Melan-A in normal skin used as control (five biopsies) showed dendritic pattern in normal melanocytes in the epidermis and it is negative in DEJ, dermis and perifollicular and periadnexal region H&E (Table/Fig 1)a, IHC (Table/Fig 1)b.

In the present study, there were 18 dermal nevi with nevus cells showing strong, diffuse pattern in the dermis and two cases where moderate and patchy staining was observed H&E (Table/Fig 2)a, IHC (Table/Fig 2)b. Five cases of compound nevi showed moderate and diffuse positivity at DEJ and dermis H&E (Table/Fig 3)a, IHC (Table/Fig 3)b. One case of deep penetrating nevus shows nests of nevi exhibiting downward streaming into the deeper dermis H&E (Table/Fig 4)a, and Melan-A showed strong, diffuse positivity at DEJ, deep dermis with perifollicular and peri adnexal sparing IHC (Table/Fig 4)b. Two cases of dysplastic nevus showed strong, diffuse pattern of nests of nevi cells at DEJ, which extended greater than three rete ridges beyond the lateral margin of dermal component H&E (Table/Fig 5)a, IHC (Table/Fig 5)b. One case of Junctional lengitneous nevus with atypia showed moderate intensity with cytoplasmic enhancement of atypical melanocytes in diffuse pagetoid pattern H&E (Table/Fig 6)a, IHC (Table/Fig 6)b. One case of spitz nevus shows strong, diffuse pattern at junction and dermal region. MELTUMP showing nests of nevus cells with atypia in the dermis H&E (Table/Fig 7)a, and Melan-A showed strong, irregular dermal diffuse positivity IHC (Table/Fig 7)b. All the cases of MM showed atypical melanocytes arranged in confluent nests invading deep dermis and prominent eosinophilic nucleoli H&E (Table/Fig 8)a, and Melan-A showed strong, diffuse positivity in dermis IHC (Table/Fig 8)b except one case with additional moderate, patchy positivity in intraepidermis and perifollicular area showed moderate positivity IHC (Table/Fig 8)c. One case of DMM showed negative Melan-A staining H&E (Table/Fig 9)a, IHC (Table/Fig 9)b. Two cases of pigmented BCC closely mimicking MM were stained with Melan-A which showed weak positivity for melanocytes with no definitive pattern between basaloid tumour cells H&E (Table/Fig 10)a, IHC (Table/Fig 10)b. Negative staining was observed in both fibro histiocytic lesion H&E
(Table/Fig 11)a, IHC (Table/Fig 11)b and MPNST for Melan-A H&E (Table/Fig 12)a, IHC (Table/Fig 12)b. All the data of melanocytic expression of Melan-A are presented in (Table/Fig 13),(Table/Fig 14),(Table/Fig 15).

Discussion

In this study, various spectrum of melanocytic lesions were encountered. Among the 50 lesions (45 cases and 5 control) in this study, benign lesions accounted for 60% of the cases, dysplastic nevi accounted for 4.4%, MELTUMP accounted for 6.6% of all the cases, lentiginous nevi with mild atypia accounted for 2.2% of all the cases, Malignant tumours accounted for 11.1% of the cases and pigmented lesion mimickers accounted for 15.5% of the cases. The lesions were most commonly seen in females with male to female ratio being 1:1.9 and the most common age range was 20-29 years.

The global incidence of non melanomatous skin lesions is 6.2% and MM is 1.6% with mortality for MM is 0.6%.In a study done in northern region of India by Labani S et al., showed incidence of melanoma of 1.62 and 1.21, in male and female, respectively (12).

Melanocytic nevi usually present in childhood and adolescents with equal sex distribution (3).The incidence of AMN ranges from 15% to 40% (2). The prevalence of atypical melanocytic nevi was 7% in all children and was age dependent (age 4-5years, 1%; 9-10 years, 4%; 14-15 years, 16%) (13).The size and number of AMN and presence of dysplastic nevi are the leading risk factors that should be recognised in the development of MM (4).

Melanocytic nevi are benign neoplasms, although may progress into MMs. Nevi are growth arrested, clonal neoplasms of melanocytes initiated by well-defined oncogenic mutations in the MAPK pathway, most commonly by BRAF activating mutation (1). BRAF-p is associated with Low-CSD melanomas (low degree of cumulative sun damage) whereas NF1, NRAS, other BRAF predominate in High-CSD melanoma of skin (14).

In young children and adolescents in whom lesions are at an early stage of development, increased pigmentation is to be anticipated. However, in adults, evidence of junctional activity is to be viewed with caution; it is those nevi with increasingly marked pigmentation, or appearing de novo in the older age groups, which are often excised for histologic evaluation. Intermittent intense sunlight is of greater importance than chronic exposure (14).

Melan-A/MART-1 is a melanocytic differentiation marker, which is recognised as an antigen on melanoma cells by cytotoxic T-lymphocytes. It is of interest for clinicians as potential immunotherapeutic target and it is relevant for pathologists as a novel diagnostic marker (15). Melan-A is useful in the differential diagnosis of melanocytic tumours, especially metastatic tumours and it also helps to distinguish between melanocytes and melanophages (melanin containing macrophages) (16).

Studies by Busam KJ et al., also tested Melan-A expression in benign melanocytic nevi and primary cutaneous melanoma. MART-1 reactivity indicates an increased immunogenicity and tumour containment by immune system (17).

A study by Orosz Z, demonstrate most of dermal nevi show strong and diffuse pattern and the staining intensity was similar in junctional and dermal components in case of spitz, compound, atypical junctional nevi (9).These findings were similar to the present study.

Deep penetrating nevus was first described in 1989 by Seab et al., Clinically this lesion is seen as a solitary darkly pigmented lesion most commonly on the extremities. It frequently affects young female patients (18). The DPN can be challenging to differentiate from cellular blue nevi, Spitz nevi, and MM. Histologically it is characterised as a well demarcated, wedge-shaped lesions reaching down into the reticular dermis/subcutis exhibiting epithelioid/spindle-cell melanocytic nests with low-grade cytological atypia and possible mitotic figures.

Spread to regional lymph nodes and metastasis with atypical features are classified as “borderline” (B-DPN) which pose a diagnostic challenge, even to experts of the dermatopathology. DPN has a good prognosis demonstrating benign behaviour (19). In a study conducted by van Ipenburg JA et al., showed diffuse expression of Melan-A with perifollicular extension (20) which is similar to the present study which showed nevus cells exhibiting downward streaming into the deeper dermis showing normal maturation. Melan-A Immunohistochemistry showed strong and diffuse positivity in DEJ, dermis, with perifollicular and peri adnexal sparing.

Dysplastic nevi showed that Melan-A had a strong intensity and diffuse staining pattern which were similar with Patrascu OM et al., study. The study showed Melan-A positivity in 80% of cases. Difference in pattern of staining was not observed with different grades of dysplasia (10).

Agusti-mejias A et al., did study of atypical lentiginous nevus shows predominance of proliferating melanocytes in the basal layer of the epidermis with focal pagetoid invasion (21) asserting the finding in the current study where Melan-A showed moderate positivity with pagetoid spread.

Elder D and Xu X, showed that Melan-A is positive in MELTUMP and strong intensity and diffuse pattern positivity which correlates to findings in the present study (22).

Major criteria that distinguish melanoma from common acquired nevi include: Size, symmetry, circumscription, ulceration, cellularity, pagetoid scatter, continuous basal proliferation, cytological atypia, mitotic activity, failure of dermal cell maturation and lympho vascular and perineural invasion (14).

Primary MM with Melan-A showed diffuse pattern in dermis in four cases and one of the cases showed moderate, patchy pattern in intraepidermal region. A case of melanoma showed a rare combination of MM and Squamous Cell Carcinoma (SCC) which have unknown biological potential, on histopathology the tumour was pigmented with atypical keratinisation and showed two morphologically distinct population of cells. The first population showed large, eosinophilic cells with signs of keratinisation. The second population was arranged in cords and nests, composed of small, pigmented, spindle and epithelioid cells.Immunohistochemical stains such as Cytokeratin 5/6 showed positivity for the pleomorphic keratinocytes, whereas Melan-A stained the atypical melanocytes (23).

When pathologist makes a diagnosis of primary MM, a series of differential diagnosis should be taken under consideration (9).

a. Benign melanocytic lesions like spitz, dysplastic nevi etc.,
b. Pigmented Soft tissue lesions

Pathologists come across a pigmented lesion should first characterise it as a melanocytic, keratinocyte, reactive process or mesenchymal. Melanocytic proliferations pose a task to the pathologist for several reasons.

1. Low-power evaluation, pigmented keratinocytes can easily be mistaken for melanocytes, so higher-power evaluation is necessary for correct morphological distinction.
2. Melanocytic proliferations are heterogenous, consideration of architectural and cytological features is needed to differentiate between diagnoses, which may be managed differently.
3. On H&E staining, interpretation can be mistaken by pigmentation secondary to either abundant melanophages or melanin/haemosiderin pigment incontinence. For such lesions bleaching techniques may be needed to clarify the cellular morphology.
4. Immunohistochemical studies may be useful adjuncts to confirm melanocytic differentiation and evaluate maturation pattern and degree of cellular proliferation (18).

Desmoplastic melanoma is a rare melanoma variant. Histologically it is made up of spindle cell component and epithelioid component. The spindle component closely mimickers sclerotic/desmoplastic nevi, non pigmented blue nevi, scar, and neural tumours. The diagnosis of DMM can be challenging due to its deceptively bland cytology. However, Melan-A along with other IHC panel can aid in diagnosis. In contrast majority of DMMs are negative for Melan-A in their spindle cell compartment (24). The current study showed negative Melan-A expression in spindled melanoma cells in DMM. In Amelanotic melanoma Melan-A, shows granular localisation in the cytoplasm (25).

Basal cell carcinoma histologically consists of nest of basaloid cells and intervening cells such as melanocytes and Langerhans cells. These melanocytes can deposit abundant pigment. They can co-exist with another tumour including MM. IHC staining with Melan-A shall rule out existence of collision tumour (pigmented BCC and MM). Brankov N et al., demonstrate that no specific pattern of melanocyte cytomorphology, configuration, or distribution was observed histologically in pigmented BCC (26), while the present study shows weak intensity for Melan-A in intervening melanocytes and was negative in tumour nests.

Study done by Luzar B and Calonje E shows that Immunohisto chemistry is thus useful in Epithelioid Benign Fibrous Histiocytoma (EBFH) to exclude its potential histological mimics. In contrast to Spitz naevus, no nesting is present in EBFH, and the cells are consistently negative for Melan-A melanocytic markers. Spitz nevus shows that Melan-A is positive and having strong intensity and diffuse pattern (27). In a study conducted by Gaspard Met al., showed Melan-A positivity in 14% cases of MPNST, whereas one case of MPNST in our study which showed negative reaction to Melan-A. MPNST caused due to sporadic causes or NF1 mutation can show positivity for Melan-A. MPNST can closely mimic spindle cell/DMM and lead to hindrance in diagnosis (28).

MPNST can morphologically resemble type C nevi cells and spindle cell melanoma. Some tumour cells can show pigmented deposition in intradermal location. Hence, are diagnosed as on histopathology as MM-nodular variant or spindle cell melanoma on morphology. IHC MelanA show negative staining helps to rule out melanocytic origin. Another study conducted by Tanas M and Rubin B Rubin showed Melan-A negative in MPNST in accordance to the present study (29). These data show the possible useful role of Melan-A in differentiating tumours that are able to mimic MM and pigmented lesions. Present results confirm and extend the findings of other researchers, that Melan-A may be a potential useful marker in correct diagnosis of melanocytic lesions and helps in differentiating from close mimicker lesions.

Limitation(s)

The limitation of this study is restricted sample size and hence significance of Melan-A staining pattern in differentiating non neoplastic and neoplastic nevi could be improvised by considering increased sample size.

Conclusion

Present study shows Melan-A is a useful marker in diagnosis of melanocytic lesions as it stains cells of melanocytic lineage and no other cell types in background. It confirms the origin of the lesion and helps to differentiate these lesions from its close mimickers aiding accurate diagnosis of melanocytic nevi.

Acknowledgement

The work was carried out as a collaboration from all the authors. Analysis and interpretation was done by Dr. R. Shubha Sangeetha. Data collection and compilation was done by Dr. Prakhar garg and Dr. Nikita Jaju. The final manuscript was approved and over viewed by all the authors including Dr. YA Manjunatha.

References

1.
Damsky WE, Bosenberg M. Melanocytic nevi and melanoma: Unraveling a complex relationship. Oncogene. 2017;36(42):5771-92. [crossref] [PubMed]
2.
Amladi S. Nevi and other Developmental Defects: IADVL Concise Textbook of Dermatology. 3rd ed. John Wiley & Sons. 2013:186.
3.
Calonje E, McKee P. McKee’s pathology of the skin. 5th ed. Edinburgh: Elsevier, Saunders. 2020:1250-51.
4.
·Iyidal AY, Gül Ü, Kýlýç A. Number and size of acquired melanocytic nevi and affecting risk factors in cases admitted to the dermatology clinic. Advances in Dermatology and Allergology. 2016;33(5):375-80. [crossref] [PubMed]
5.
Pandhi I, Pandhi SB, Pandhi SA, Pandhi SI. Melanocytic tumours of the skin: A dermatopathological review. Pigmentary Disorders. 2014;1:118. Doi: 10.4172/2376-0427.1000118. [crossref]
6.
Kamyab-Hesary K, Ghanadan A, Balighi K, Mousavinia SF, Nasimi M. Immunohistochemicalstaining in the assessment of melanoma tumour thickness. Pathol Oncol Res. 2020;26(2):885-91. [crossref] [PubMed]
7.
Bohra I, Paudyal P, Pradhan A, Khadka DK. Pigmented skin lesions clinicohistopathological correlation: A hospital based study at BPKIHS. J Pathol Nep. 2019;9:1950-54. [crossref]
8.
Chen YT, Stockert E, Jungbluth A, Tsang S, Coplan KA, Scanlan MJ, et al. Serological Analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA. 1996;93(12):5915-19. [crossref] [PubMed]
9.
Orosz Z. Melan-A/Mart-1 expression in various melanocytic lesions and in non melanocytic soft tissue tumours. Histopathology. 1999;34(6):517-25. [crossref] [PubMed]
10.
Patrascu OM, Costache M, Dumitru AV, Mehotin CN, Sajin M, Lazaroiu AM, et al. Expression of Bcl-2, Melan-A and HMB-45 in dysplastic Nevi. Maedica (Bucur). 2016;11(1):38-43.
11.
Bergman R, Azzam H, Sprecher E, Manov L, Munichor M, Friedman-Birnbaum R, et al. A comparative immunohistochemical study of MART-1 expression in spitz nevi, ordinary melanocytic nevi, and malignant melanomas. J Am Acad Dermatol. 2000;42:496-500. [crossref]
12.
Labani S, Asthana S, Rathore K, Sardana K. Incidence of melanoma and nonmelanoma skin cancers in Indian and the global regions. J Cancer Res Ther. 2021;17(4):906-11. [crossref] [PubMed]
13.
Valiukeviciene S, Miseviciene I, Gollnick H. The prevalence of common acquired melanocytic nevi and the relationship with skin type characteristics and sun exposure among children in Lithuania. Archives of Dermatology. 2005;141:579-86. [crossref] [PubMed]
14.
Elder D, Massi D, Scolyer R, Willemze R. WHO classification of skin tumours. 4th ed. 2018:66-67.
15.
Busam KJ, JungbluthA. Melan-A, A new melanocytic differentiation marker. Advances in Anatomic Pathology. 1999;6(1):12-18. [crossref] [PubMed]
16.
Bancroft J, Gamble M. Theory and Practical of Histological Techniques. Philadeiphia:Churchill Living stone. 7th ed. Elsevier. 2011:251.
17.
Busam KJ, Chen YT, Old LJ, Stockert E, Iversen K, Coplan KA, et al. Expression of Melan-A (MART-1) in benign melanocytic nevi and primary cutaneous melanoma. Am J Surg Pathol. 1998;22:976-82. [crossref] [PubMed]
18.
Aung PP, Mutyambizi KK, Danialan R, Ivan D, Prieto VG. Differential diagnosis of heavily pigmented melanocytic lesions: Challenges and diagnostic approach. J Clin Pathol. 2015;68:963-70. [crossref] [PubMed]
19.
Cosgarea I, Griewank KG, Ungureanu L, Tamayo A,Siepmann T. Deep penetrating nevus and borderline-deep penetrating nevus: A literature review. Front Oncol. 2020;10:837. [crossref] [PubMed]
20.
Van Ipenburg JA, Damman J, Paridaens D, Verdijk RM. Histopathological and molecular features of a conjunctivalcaruncular deep penetrating nevus. Ocul Oncol Pathol. 2020;6(4):293-96. [crossref] [PubMed]
21.
Agustí-Mejias A, Messeguer Badiab F, García Ruiza R, Oliver Martíneza V, Alegre de Mique lV. Atypical Lentiginous Nevus: A clinical and histopathologic study of 14 cases. Actas Dermosifiliogr. 2012;103(5):394-400. [crossref] [PubMed]
22.
Elder D, Xu X. The approach to the patient with a difficult melanocytic lesion. Pathology. 2004;36(5):428-34. [crossref] [PubMed]
23.
Kochoumian E, Kazlouskaya V, Mangold A,Lal K, Maia-Cohen S, Elston DM. Tumour with the features of both squamous cell carcinoma and melanoma (melanocarcinoma). Indian Dermatol Online J. 2015;6:217-19. [crossref] [PubMed]
24.
Kucher C, Zhang P, Pasha T, Elenitsas R, Wu H, Ming M, et al. Expression of Melan-A and Ki-67 in Desmoplastic Melanoma and Desmoplastic Nevi. The American Journal of Dermatopathology. 2004;26(6):452-57. [crossref] [PubMed]
25.
Pandiar D, Basheer S, Shameena P, Sudha S, Dhana L. Amelanotic Melanoma Masquerading as a Granular Cell Lesion. 2013. [crossref] [PubMed]
26.
Brankov N, Prodanovic E, Hurley M. Pigmented basal cell carcinoma: Increased melanin or increased melanocytes? Journal of Cutaneous Pathology. 2016;43(12):1139-42. [crossref] [PubMed]
27.
Luzar B, Calonje E. Cutaneous fibrohistiocytic tumours- an update. Histopathology. 2010;56(1):148-65. [crossref] [PubMed]
28.
Gaspard M, Lamant L, Tournier E, Valentin T, Rochaix P, Terrier P, et al. Evaluation of eight melanocytic and neural crest-associated markers in a well-characterised series of 124 malignant peripheral nerve sheath tumours (MPNST): Useful to distinguish MPNST from melanoma. Histopathology. 2018;73(6):969-82. [crossref] [PubMed]
29.
Tanas M, Rubin B. Malignant neuroectodermaltumour with melanocytic and rhabdomyoblastic differentiation. Rare Tumours. 2009;1(2):79-81. [crossref] [PubMed]

DOI and Others

DOI: 10.7860/JCDR/2022/53438.16154

Date of Submission: Nov 24, 2021
Date of Peer Review: Jan 09, 2022
Date of Acceptance: Mar 02, 2022
Date of Publishing: Apr 01, 2022

AUTHOR DECLARATATION:
• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. NA

PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Nov 25, 2021
• Manual Googling: Jan 22, 2022
• iThenticate Software: Jan 25, 2022 (19%)

ETYMOLOGY: Author Origin

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com